

PHASE 1 2017 – 2018 <i>Initiation: Literature Review</i>	PHASE 2 2019 – 2020 <i>Development: Qualitative</i>	PHASE 3 2020 – 2021 <i>Acquisition & Data Reporting: Quantitative</i>	PHASE 4 2021 <i>Activation: Data Gathering</i>	PHASE 5 2022+ <i>Application</i>
OBJECTIVES				
<ul style="list-style-type: none"> Conduct global scientific scan of patient reported outcomes literature. Develop database of patient organizations. 	<p>Qualitative Data:</p> <ul style="list-style-type: none"> Identify issues associated with the patients' diseases. Develop new methodology (called GRIP) to collect impact areas. Gather primary data from patients via focus groups and interviews. Analyze and collate data. Conduct Delphi process to validate and affirm the data. 	<p>Quantitative Data:</p> <ul style="list-style-type: none"> Develop new patient impact measurement tool (called PRIDD patient impact). Acquire global patient impact data using PRIDD patient impact measurement tool. Further test validity of PRIDD patient impact measurement tool. 	<ul style="list-style-type: none"> Analyze data using psychometric testing. Launch PRIDD patient impact measurement tool globally. Report scale development and peer review processes. 	<ul style="list-style-type: none"> Disseminate GRIDD patient impact data. Publish articles and reports. Educate stakeholders and public. Deliver advocacy campaigns. Offer patient organizations' leaders training and support.
OUTCOMES				
<ul style="list-style-type: none"> 12,927 scientific articles reviewed. Patient impact dataset created. 36 dermatology-specific patient-reported measures identified. No measure met Cosmin Category A criteria (i.e. none met gold standard). 	<ul style="list-style-type: none"> GRIDD dataset enriched and data gaps filled via two rounds of primary impact interviews with patients that represent all continents. Poster sessions and paper(s) published on GRIDD research. 	<ul style="list-style-type: none"> Pilot and test PRIDD – gold standard patient impact measurement tool. Poster sessions and paper(s) published on GRIDD research. 	<ul style="list-style-type: none"> Final version of PRIDD patient impact measurement tool developed and launched globally. Poster sessions and paper(s) published on GRIDD research. 	<ul style="list-style-type: none"> Open source data to: <ul style="list-style-type: none"> Produce publications and reports. Support advocacy. Improve public policy. Validate patients' voices. Poster sessions and paper(s) published on GRIDD research.



BENEFITS of GRIDD			
<p>PATIENT ORGANIZATIONS</p> <ul style="list-style-type: none"> Access to dataset from PRIDD - World's first dermatology patient impact measurement tool. Evidence to support their missions and fundraising. Training, resources to support their work and in turn their patients. Patients' voice integrated in future decision-making. 	<p>DATA & EVIDENCE</p> <ul style="list-style-type: none"> Gap in patient-driven research now filled which will: <ul style="list-style-type: none"> Support publications and reports. Advance research employing the PRIDD patient impact measurement tool. Inform better public health policy. 	<p>ADVOCACY & COMMUNICATIONS</p> <ul style="list-style-type: none"> Provide support for GlobalSkin member campaigns to advance their priorities. Educate via a global campaign customized by disease and by country (i.e. language). Facilitate informed advocacy at local, regional and country levels to improve diagnosis, care and access to treatments. 	<p>GLOBAL DERMATOLOGY</p> <ul style="list-style-type: none"> Advocate via a global campaign to advance dermatology. Build a collaborative global network of dermatology stakeholders working towards the shared objectives of better care and treatment for patients. Elevate the Disability Adjusted Life Years (DALY) ranking for dermatology (used by the WHO for setting global health priorities).